Alzheimer's - Dementia, Author Interviews, Baylor College of Medicine Houston, NEJM / 02.02.2014
Alzheimer’s Disease: Solanezumab Trials for Mild to Moderate Disease
MedicalResearch.com Interview with:
Rachelle S. Doody, M.D.,Ph.D.
Effie Marie Cain Chair in Alzheimer's Disease Research
Director, Alzheimer's Disease and Memory Disorders Center
Baylor College of Medicine-Department of Neurology
Houston, Texas 77030: MedicalResearch.com
MedicalResearch.com: What are the main findings of the study?
Dr. Doody: The study set out to see whether the antibody infusion treatment, Solanezumab, would improve the course of mild to moderate Alzheimer's disease in the ways necessary to gain drug approval. Unfortunately, the results did not support an approvable treatment for this purpose.



















